These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 19181929

  • 1. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C.
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [Abstract] [Full Text] [Related]

  • 2. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL.
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [Abstract] [Full Text] [Related]

  • 3. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
    Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F.
    Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
    [Abstract] [Full Text] [Related]

  • 4. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
    Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, Kallenberg GG.
    J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
    [Abstract] [Full Text] [Related]

  • 5. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus.
    Wang H, Xu J, Ji X, Yang X, Sun K, Liu X, Shen Y.
    Cell Immunol; 2005 Jun; 235(2):117-21. PubMed ID: 16226734
    [Abstract] [Full Text] [Related]

  • 6. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ.
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
    Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T.
    Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: contribution to Fas-mediated apoptosis.
    Pyrovolaki K, Mavroudi I, Sidiropoulos P, Eliopoulos AG, Boumpas DT, Papadaki HA.
    Arthritis Rheum; 2009 Feb; 60(2):543-52. PubMed ID: 19180486
    [Abstract] [Full Text] [Related]

  • 11. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M.
    Anticancer Res; 2001 Feb; 21(4B):3053-9. PubMed ID: 11712810
    [Abstract] [Full Text] [Related]

  • 12. Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules.
    Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z.
    Immunol Invest; 2010 Feb; 39(1):27-38. PubMed ID: 20064083
    [Abstract] [Full Text] [Related]

  • 13. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S, Abraham P, Daniel HD, Ramakrishna BS, Sridharan G.
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [Abstract] [Full Text] [Related]

  • 14. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
    Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Harris J, Hoi AY, Mackay F, Morand EF.
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
    [Abstract] [Full Text] [Related]

  • 15. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B, Uzaslan E, Budak F, Karadağ M, Ediger D, Oral B, Göral G, Ege E, Gözü O.
    Tuberk Toraks; 2005 Jun; 53(2):127-31. PubMed ID: 16100648
    [Abstract] [Full Text] [Related]

  • 16. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
    Onalan G, Selam B, Baran Y, Cincik M, Onalan R, Gündüz U, Ural AU, Pabuccu R.
    Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
    [Abstract] [Full Text] [Related]

  • 17. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
    Endo S, Inoue Y, Fujino Y, Yamada Y, Sato N, Wakabayashi G, Sakamoto T, Ishikura H, Tanaka T, Inada K, Sato S.
    Res Commun Mol Pathol Pharmacol; 2000 Sep; 108(3-4):179-86. PubMed ID: 11913710
    [Abstract] [Full Text] [Related]

  • 18. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S.
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
    [Abstract] [Full Text] [Related]

  • 19. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
    Habib HM, Taher TE, Isenberg DA, Mageed RA.
    Scand J Rheumatol; 2009 Nov; 38(2):112-20. PubMed ID: 19110660
    [Abstract] [Full Text] [Related]

  • 20. [Studies on Fas ligand expression in patients with systemic lupus erythematosus].
    Feng Y.
    Hokkaido Igaku Zasshi; 1997 Jul; 72(4):443-55. PubMed ID: 9266252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.